DCTH241220P10000
- 0.05
- 0.000.00%
Delcath Systems Newsroom
Delcath Systems (NASDAQ:DCTH) Delivers Shareholders Incredible 358% Return Over 1 Year, Surging 20% in the Last Week Alone
CCORF Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $21
Delcath Systems Announces FDA Clearance Of IND Application For Phase 2 Clinical Trial Of HEPZATO In Combination With Standard Of Care In Liver-Dominant Metastatic Colorectal Cancer
Express News | Delcath Systems Inc - Primary Endpoint Data Expected by End of 2027
Express News | Delcath Systems Announces FDA Clearance of Ind Application for Phase 2 Clinical Trial of Hepzato™ in Liver-Dominant Metastatic Colorectal Cancer
H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $22
Delcath Systems: Strong Financial Performance and Strategic Growth Drive Buy Rating
Delcath Systems Reports Strong Q3 Growth and Expansion
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript
Craig-Hallum Maintains Delcath Systems(DCTH.US) With Buy Rating, Announces Target Price $11
Here Are the Major Earnings After the Close Today
Delcath Systems | 10-Q: Q3 2024 Earnings Report
Delcath Systems | 8-K: Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
Delcath Systems Reports Q3 EPS 6c, Consensus (20c)
Express News | Delcath Systems Inc Q3 Shr View $-0.20 -- LSEG IBES Data
Express News | Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
Express News | Delcath Systems Q3 Gross Profit USD 9.56 Million
Express News | Delcath Systems Q3 Operating Income USD -1.259 Million Vs. IBES Estimate USD -4.16 Million
Press Release: Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
Delcath Systems 3Q EPS 6c >DCTH